Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
| Contract | Contractor | Type | States |
|---|---|---|---|
| 15102 | CGS Administrators, LLC | MAC - Part B | KY |
| 15202 | CGS Administrators, LLC | MAC - Part B | OH |
| 15101 | CGS Administrators, LLC | MAC - Part A | KY |
| 15201 | CGS Administrators, LLC | MAC - Part A | OH |
Billing and coding article A59860: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59860 (Billing and Coding: MolDX: Genetic Testing in Heritable Thoracic Aortic Disease) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.
A59860: Billing and Coding: MolDX: Genetic Testing in Heritable Thoracic Aortic Disease (Billing and Coding, effective 2026-10-01)
- Covered ICD-10-CM codes
- 11
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 3
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| I71.010 | Dissection of ascending aorta |
| I71.011 | Dissection of aortic arch |
| I71.11 | Aneurysm of the ascending aorta, ruptured |
| I71.12 | Aneurysm of the aortic arch, ruptured |
| I71.21 | Aneurysm of the ascending aorta, without rupture |
| I71.22 | Aneurysm of the aortic arch, without rupture |
| Q25.43 | Congenital aneurysm of aorta |
| Q25.44 | Congenital dilation of aorta |
| Q79.63 | Vascular Ehlers-Danlos syndrome |
| Q87.410 | Marfan syndrome with aortic dilation |
| Q87.A | Loeys-Dietz syndrome |
Procedure codes: 81410, 81411, 81479.
Coverage indications, limitations and medical necessity
This policy defines coverage for Lab-Developed Tests (LDTs), Federal Drug Administration (FDA)-cleared, and FDA-approved clinical laboratory tests for heritable thoracic aortic disease including Next Generation Sequencing (NGS) tests. This policy’s scope is specific for hereditary germline testing.
Criteria for Coverage
Genetic testing for Heritable Thoracic Aortic Disease (HTAD) is covered when ALL the following are met:
• The patient presents with an aortic root/ascending aortic dilation, aneurysm or dissection (as defined by national consensus guidelines) AND at least one of the following are true:
• Presentation before age 60 years, OR
• Presence of syndromic features of Marfan syndrome, Loeys-Dietz syndrome, or vascular Ehlers-Danlos syndrome, OR
• Family history of thoracic aortic disease or peripheral/intracranial aneurysm in a first- or second-degree relative, OR
• Family history of unexplained sudden death at a relatively young age in a first- or second-degree relative.
• Demonstration that the patient has been offered counseling regarding the test and potential results.
• The test performed includes at least the minimum genetic content (genes or genetic variants) with definitive or well-established guidelines-based evidence (as determined by ClinGen and the American College of Cardiology (ACC) and American Heart Association (AHA) Guideline for the Diagnosis and Management of Aortic Disease) required for clinical decision making for its intended use that can be reasonably detected by the test. A single variant may be tested if it is the only variant considered to be reasonable and necessary for a patient given that it is a known familial variant.
• The test does not include additional genetic content that is not properly validated, or of unclear clinical validity or utility such that it could reasonably or possibly be mis-utilized by the patient or treating physician and result in impaired patient outcomes.
• Testing does not conflict with other applicable policy, specifically provisions of repeat germline testing defined in L38274.
• The test has satisfactorily completed a Technical Assessment (TA) by Molecular Diagnostic Services Program (MolDX ® ).
Summary of evidence (opening)
Thoracic aortic aneurysms (TAA) occur with an incidence of approximately 5 to 10 per 100,000 individuals per year. 1-4 The incidence is similar in men and women, but the average age at diagnosis is a decade higher in women (70s) than in men (60s). 5 The etiology and location of a given TAA dictates its natural history and the approach to management. Medical literature and guidelines define the aorta into five main anatomic segments: the root or sinus segment, which extends from the aortic valve annulus to the sinotubular junction; the ascending thoracic aorta, which extends from the sinotubular junction to the innominate artery; the aortic arch, which extends from the innominate to the left subclavian artery; the descending thoracic aorta, which extends from the left subclavian artery to the diaphragm; and the abdominal aorta, which extends from the diaphragm to the level of the aortic bifurcation. 4,6 A true aneurysm is a segmental full-thickness dilation of the blood vessel that affects the three layers of the arterial wall (intima, media, adventitia). 4 Acute aortic dissection (AAD) of the ascending aorta is defined according to the DeBakey (Type I, Type II) or Stanford classification scheme (Type A). 4 Approximately 60% of TAAs are found at the aortic root or ascending aorta, 40% occur in the descending aorta, 10% are localized to the aortic arch, and 10% to the thoracoabdominal aorta. 7 Notably, a TAA can involve more than one aortic segment. 3,7 Most TAAs are asymptomatic and discovered incidentally when imaging studies, such as chest x-rays, CT scans, or echocardiograms are performed for seemingly unrelated indications. 3 When symptomatic, TAAs can present with upper back or chest pain, as well as compression-related symptoms affecting the surrounding structures, leading to nerve dysfunction or arterial compression with ischemia or thromboembolism. 3 Aneurysms of the aortic root or ascending aorta may result in secondary aortic regurgitation with an accompanying diastolic murmur. 3 Nevertheless, the vast majority of TAAs are asymptomatic before an acute event and a high mortality rate is associated with aortic rupture or dissection, with an early mortality of 1% to 2% per hour after onset of symptoms following acute aortic dissection of the ascending aorta. 4,8 TAAs account for approximately one third of hospitalizations related to aortic aneurysms, with the remaining two thirds occurring due to aneurysms of the abdominal aorta. 4
The etiology and natural history of a TAA are the most important considerations in determination of diameter thresholds for the purpose of clinical management. 4 Correlation of aortic diameter with body size and sex is also key in threshold determination. 5 A community study by Paruchuri et al demonstrated an increased risk of type A aortic dissection between 4.0 cm and 4.4 cm when compared to a control diameter of ≤ 3.4 cm. 9 This in turn formed the basis for the definition of a dilated ascending aorta as ≥ 4.0 cm by the American College of Cardiology (ACC) and American Heart Association (AHA) Guideline for the Diagnosis and Management of Aortic Disease 4 (ACC/AHA Guidelines) and is congruent with the 2014 European Society of Cardiology guideline on the diagnosis and treatment of aortic diseases, in which aortic dilation was similarly defined as a diameter of the ascending aorta > 4.0 cm. 4,10 Subsequently, the abrupt increase in risk at a diameter of ≥ 4.5 cm justifies definition of an aneurysm. 9 These thresholds apply to individuals whose height, body surface area (BSA) or both are within 1-2 standard deviations of the population mean and may need to be adjusted downward or upward depending on the individual. 4 Risk assessment can also be conducted using aortic z-scores and other diameter indexing methods. 4
TAAs can be caused by congenital conditions, heritable disorders, multifactorial degenerative conditions, previous aortic dissection, infections, and inflammatory diseases. 2,4,11 Heritable causes are more likely to be identified for aortic root aneurysms and aneurysms of the ascending thoracic aorta, which are more likely to present at a younger age (60 years) when compared with aneurysms of the descending aorta (72 years). 4,12 Ascending TAAs also typically lack risk factors for atherosclerosis, such as diabetes, hypertension, and smoking and demonstrate low prevalence of aortic calcifications or atheromas, which are more prevalent in descending TAAs, wherein these “degenerative” injuries are considered preconditions. 4,12 Aortic root and ascending thoracic aortic aneurysms are also often associated with bicuspid aortic valve (BAV). Finally, many aortic root and ascending thoracic aortic aneurysms are sporadic and idiopathic in nature. 4
A variety of genetic or heritable conditions are thought to account for approximately 20% of TAAs; collectively, these are referred to as heritable thoracic aortic disease (HTAD). This encompasses syndromic HTAD, which is associated with multiorgan features, and nonsyndromic HTAD, wherein abnormalities are limited to the aorta with or without its branches. 4,13 HTAD is most often is associated with aneurysms of the aortic root, ascending aorta, or both, but may present with distal aortic disease and aortic dissection and pathogenic variants in multiple genes can lead to TAA, cerebral aneurysms, and abdominal aortic aneurysms (AAA). For example, mutations in TGFBR2 predispose to TAA as well as intracranial aneurysms and aneurysms and dissections of other arteries. 4 ACTA2 mutations lead to TAA and occlusive vascular disease, including early onset stroke and coronary artery disease. 4
The contractor cites 24 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2025-08-17
- Current revision effective
- 2026-06-25
- Last reviewed by the contractor
- 2026-06-17
- MCD version
- 5
Other related documents: A60199 (Response to Comments).
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the CGS Administrators, LLC hub lists every other active policy from the same contractor.
The same policy title at other contractors
Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L39938 cover?
• Testing does not conflict with other applicable policy, specifically provisions of repeat germline testing defined in L38274. The full 326-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L39938 apply to?
CGS Administrators, LLC applies it to Medicare claims in 2 states: KY, OH. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L39938?
The companion billing and coding article A59860 lists 11 ICD-10-CM codes in 1 group that support medical necessity; the first 11 appear on this page, where the complete list opens by group with the contractor's group instructions.
How do I appeal a denial under LCD L39938?
A denial under LCD L39938 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59860's 11 covered diagnosis codes, then file a redetermination with CGS Administrators, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.